Ribozyme closes $48mm private financing

Ribozyme Pharmaceuticals (nucleic acid technologies) closed a $48mm private financing of 145.45mm common shares priced at $0.33 each (a 22% premium to market average) and five-year warrants to buy 30mm more common shares at $0.42. Investors (and their post-offering stakes in the company) are Sprout Group (41.8%), Venrock Associates (18.9%), Oxford Bioscience (14.2%), Techno Venture Management (9.2%), and Granite Global Ventures (fund sponsored by Venrock, Singapore Economic Development Board, and U.S. Bancorp Piper Jaffray) (3.7%).